Northland Securities analyst Tim Chiang reiterated a Buy rating on Amphastar Pharmaceuticals (AMPH) today and set a price target of $23.00. The company’s shares closed last Thursday at $18.05.
According to TipRanks.com, Chiang is a 1-star analyst with an average return of -2.3% and a 44.4% success rate. Chiang covers the Healthcare sector, focusing on stocks such as Verrica Pharmaceuticals, Pacira Pharmaceuticals, and Kala Pharmaceuticals.
Currently, the analyst consensus on Amphastar Pharmaceuticals is a Moderate Buy with an average price target of $22.33.
See today’s analyst top recommended stocks >>
Amphastar Pharmaceuticals’ market cap is currently $860.8M and has a P/E ratio of 693.20. The company has a Price to Book ratio of 2.37.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Amphastar Pharmaceuticals, Inc. engages in the development, manufacture, market, and sale of technically challenging and proprietary injectable, inhalation, and intranasal products. It operates through Finished Pharmaceutical Products, and Active Pharmaceutical Ingredients Products segments. The Finished Pharmaceutical Products segment manufactures, markets and distributes enoxaparin, cortrosyn, amphadase, naloxone, lidocaine jelly, as well as various other critical and non-critical care drugs. The Active Pharmaceutical Ingredients Products segment manufactures and distributes recombinant human insulin and porcine insulin. The company was founded by Zi-Ping Luo and Yong Feng Zhang on February 29, 1996 and is headquartered in Rancho Cucamonga, CA.
Read More on AMPH:
